What would you like to look for?
Site search
Search filters

SHS invests in Simulands AG

6 March 2023

The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions.

A fund advised by AFINUM Management AG buys GS Swiss PCB

12 October 2021

A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.

CombiGene and Spark enter global licensing agreement for gene therapy

12 October 2021

STOCKHOLM - CombiGene AB and Spark Therapeutics announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project.

evitria Group sold to Atlas Antibodies, Sweden

9 August 2021

The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.

Global Development Alliance between Numab Therapeutics and Kaken Pharmaceutical

2 February 2021

On January 13, 2021, Numab Therapeutics AG (Wädenswil, Switzerland) entered into a global co-development and regional licensing agreement with Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) for Numab's novel multispecific anti-inflammatory drug candidate NM26- 2198, which blocks three key pathways in the pathophysiology of atopic dermatitis.

MCAM Symalit acquires Recycling Activities from Minger Kunststofftechnik

2 April 2020

MCAM Symalit AG, Lenzburg, a group company of the Mitsubishi Chemical Advanced Materials group, a leading global manufacturer of high-performance materials, takes over all Recycling related activities and assets, current...

Numab and Sunshine Guojian form partnership

20 December 2019

3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...

NUMAB concludes Licensing and Development Agreement in China

2 May 2019
29 April 2019

Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...

AFINUM acquires majority stake in evitria AG

31 December 2018
19 February 2019

AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in the Schlieren (Switzerland) based biotech company evitria AG from its founder. evitria AG is one of the leading providers of custom antibodies for...

US / Swiss health solution provider group acquires Swiss pharmacy

29 May 2018

A US / Swiss health solution provider group based in Geneva and Pennsilvania acquired a Swiss pharmacy from its founder. VISCHER acted as transaction counsel to the buyer.

The VISCHER team was led by Felix W. Egli and further...